M&A Deal Summary

Advent International Acquires Zentiva

On April 17, 2018, private equity firm Advent International acquired life science company Zentiva from Sanofi for 1.9B EUR

Acquisition Highlights
  • This is Advent International’s 12th transaction in the Life Science sector.
  • This is Advent International’s 14th largest (disclosed) transaction.
  • This is Advent International’s 6th transaction in Czech Republic.

M&A Deal Summary
Date 2018-04-17
Target Zentiva
Sector Life Science
Buyer(s) Advent International
Sellers(s) Sanofi
Deal Type Divestiture
Deal Value 1.9B EUR

Target

Zentiva

Prague, Czech Republic
Zentiva is a generics pharmaceutical company, offering generic medicines across all key therapeutic areas. Zentiva is headquartered in Prague, Czech Republic.

Search 200,500 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Advent International

Boston, Massachusetts, United States

Investor Investor Investor Investor Investor

Category Private Equity Firm
Founded 1984
PE ASSETS 76.0B USD
Size Mega
Type Sector Agnostic
DESCRIPTION

Advent is a global private equity firm that targets investments in North America, Europe, Asia, and Latin America. Advent's emerging market efforts are concentrated in Central Europe and Latin America. Advent seeks transactions valued between $50 million and $5 billion and can commit up to $2 billion of equity capital per investment. Broad areas of interest include business & financial services, retail & consumer, technology, media, & telecoms, healthcare & life sciences, and industrial. Prospective transaction types include buyouts, growth capital financings, take privates, and recapitalizations. Advent was formed in 1984 and is based in Boston, Massachusetts.

DEAL STATS #
Overall 261 of 339
Sector (Life Science) 12 of 21
Type (Divestiture) 19 of 37
Country (Czech Republic) 6 of 6
Year (2018) 6 of 10
Size (of disclosed) 14 of 47
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2018-03-30 Clearent

Creve Coeur, Missouri, United States

Clearent is a provider of full-service, payment solutions that leverages its proprietary payments platform to make doing business easier and more profitable for its sales partners. Clearent was founded in 2005 and is based in Creve Coeur, Missouri.

Buy -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2018-05-07 MORSCO

Forth Worth, Texas, United States

MORSCO, Inc. is a wholesale distributor of plumbing, HVAC, and builder products in the Southwest. Sovos Brands is a new kind of food and beverage company with a mission to acquire and build one-of-a-kind brands. Its portfolio includes Michael Angelo’s Gourmet Foods, a leading producer of premium, authentic frozen Italian entrées, and Rao’s Specialty Foods, a producer of super premium pasta sauce and other Italian specialty foods. Founded in 1917, Morrison now operates approximately eighty locations in Texas, New Mexico, Oklahoma, Kansas, and Louisiana.

Sell $1.4B

Seller(S) 1

SELLER

Sanofi

Paris, France
Category Company
Founded 1994
Sector Life Science
Employees86,088
Revenue 46.4B EUR (2023)
DESCRIPTION

Sanofi is a French multinational pharmaceutical company headquartered in Paris, France, the world's fourth-largest by prescription sales. Sanofi was founded in 1994 and is based in Paris, France.

DEAL STATS #
Overall 8 of 14
Sector (Life Science) 6 of 8
Type (Divestiture) 8 of 14
Country (Czech Republic) 1 of 1
Year (2018) 2 of 4
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2018-02-01 Sanofi SA - Leukine

Paris, France

Sanofi SA - Leukine is an immuno-stimulant that promotes the growth and activation of a broad range of white blood cells important in activating the body's immune response to fight infections.

Sell -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2018-06-18 Sanofi SA - Infectious diseases

Paris, France

Sanofi SA - Infectious diseases are caused by bacteria, viruses, fungi or parasites and can be spread, directly or indirectly, from one person to another. Treatments for infectious diseases include antibiotics and anti-viral medications. Today, infectious diseases propagated by bacteria are becoming increasingly resistant to many antibiotics and any use of antibiotics reduces the effectiveness of these drugs for other patients. The World Health Organization (“WHO”) has deemed antibiotic resistance to be one of the three greatest threats to human health today. Almost a million people die of resistant infections a year. It is also estimated that by 2050, 10 million lives a year and a cumulative 100 trillion dollars of economic output are at risk due to the rise of drug resistant infections, if solutions to this problem are not identified now. Thus, there is a critical need to research and develop medical solutions to combat antibiotic resistant bacteria.

Sell -
Mergr

Product

Company

Legal